Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Claritas Pharmaceuticals- Our Company

<< Previous

Bullboard Posts

Next >>

Comment by Captainblkon Feb 11, 2021 6:26pm

141 Views

Post# 32547737

RE:Claritas Pharmaceuticals- Our Company

It is rather odd to me that they are "headquartered in San Fran," their leased out of a lab in Beverly, Mass., and AL Salzman lists Claritas Pharma as Vancouver Based:

for what its worth, at least bob is listed as living near San Fran according to google
41 Thunderbird Dr - Google Maps

Overview - Claritas Pharmaceuticals (googleusercontent.com)

Claritas Pharmaceuticals is headquartered in San Francisco, CA. The Company has leased recently renovated 8,500 square feet of laboratory, office, and archival space in Beverly, Massachusetts, fully-equipped with state-of-the-art systems to carry out analytical, bioanalytical, and synthetic chemistry activities.

Andrew Salzman - Founder and Chairman of the Board - Salzman Group | LinkedIn